AEON Biopharma, Inc. - 8-K Filing

AEON Biopharma reports Q3 2026 results, secures $6.2M in warrant proceeds, and advances ABP-450 biosimilar development following FDA Type 2b feedback. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statement and Exhibits)

SEC EDGAR ·

Tickers: $AEON

Read the full article at SEC EDGAR

More Regulatory news